Further to its press release dated August 12, 2022, Core One Labs Inc. (CSE: COOL | OTCQB: CLABF | Frankfurt: LD6 | WKN: A3CSSU) is pleased to announce that its wholly-owned subsidiary Vocan Biotechnologies Inc. has successfully employed enzymatic production methods to convert a chemically produced psilocin developed by the Company’s recently acquired Awakened Biosciences Inc.’s, into viable API psilocybin.
Awakened has produced approximately 220 grams (g) of a psilocin precursor which it can convert into a minimum of 125g of psilocin, the psychoactive ingredient in psilocybin. This, using Vocan’s production technology, can be transformed into, about 160 g of contaminant free psilocybin, at a 100% success rate. To date, Vocan has successfully transformed psilocin into psilocybin at their lab.
The successful test batch results and the quantity and purity of psilocybin being produced in Vocan’s research purposed lab facility, within such a short period of time, emphasizes the efficiency of their production technology. The Company anticipates that furnishing Vocan’s current lab facilities with small scale production purposed equipment will result in significantly increased yields, and further anticipates mass production capabilities with the engagement of a GMP compliant contract development and manufacturing organization (CDMO).
“The renaissance of psychedelics medicine as an alternative means to addressing mental health afflictions has been making significant strides in the last decade, and I am very confident when I say that Core One is doing its part from an early onset,” “Our team of scientists, and their groundbreaking collaborations are putting Core One ‘on the map’; not only as leading innovators in psychedelics research and development, but also as a ‘one stop shop’ for patients, physicians and researchers, alike. With a growing body of research, and an increased openness to evaluate psychedelic treatments on its merits, rather than on historic myths and misnomers, Core One feels that demand for access to psychedelic medicines and psychedelic-assisted treatments will also continue increase. We are committed to meeting the anticipated demands and by doing so we will continue to grow shareholder value.”
Joel Shacker, Core One CEO.
About Core One Labs Inc.
Core One Labs is a life sciences biotechnology research and development company focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, the advancement of psychedelic assisted treatments, and the integration of novel delivery systems technology.